<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03965728</url>
  </required_header>
  <id_info>
    <org_study_id>19401</org_study_id>
    <secondary_id>2019-000632-26</secondary_id>
    <nct_id>NCT03965728</nct_id>
  </id_info>
  <brief_title>Study to Investigate Safety, Tolerability, Pharmacokinetics, and Drug-drug Interaction of Multiple Oral Doses of BAY1830839 in Healthy Male Participants</brief_title>
  <official_title>Multiple Dose Escalation Study in a Randomized, Double-blind, Placebo-controlled Design to Investigate Safety, Tolerability, Pharmacokinetics, Drug-drug Interaction and Exploratory Pharmacodynamics of Multiple Oral Doses of BAY1830839 in Healthy Male Participants</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bayer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bayer</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this study is to investigate safety, tolerability and pharmacokinetics of&#xD;
      increasing repeated oral doses of BAY1830839 in healthy male participants including the&#xD;
      investigation of any potential drug-drug interactions of BAY1830839 with midazolam and&#xD;
      methotrexate. In addition, the effects of BAY180839 on exploratory pharmacodynamics&#xD;
      biomarkers in healthy participants will be investigated.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 5, 2019</start_date>
  <completion_date type="Anticipated">March 14, 2022</completion_date>
  <primary_completion_date type="Anticipated">December 23, 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Frequency of TEAEs</measure>
    <time_frame>7 days (period 1)</time_frame>
    <description>TEAE: treatment-emergent adverse event</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Frequency of TEAEs</measure>
    <time_frame>18 days (period 2)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Severity of TEAEs</measure>
    <time_frame>7 days (period 1)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Severity of TEAEs</measure>
    <time_frame>18 days (period 2)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC(0-24)md of BAY1830839 (QD and TID dosing)</measure>
    <time_frame>Day 1 period 1</time_frame>
    <description>QD:once daily administration TID: three times daily administration</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC(0-12)md of BAY1830839 (BID dosing only)</measure>
    <time_frame>Day 1 period 2</time_frame>
    <description>BID:twice daily administration</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Cmax,md of BAY1830839 after multiple dosing</measure>
    <time_frame>18 days (period 2)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Cav of BAY1830839 after multiple dosing</measure>
    <time_frame>18 days (period 2)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC of midazolam in plasma in presence/absence of BAY1830839</measure>
    <time_frame>Day -1 period 1</time_frame>
    <description>If AUC(tlast-∞) &gt;20% of AUC then AUC(0-tlast) will replace AUC.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Cmax of midazolam in plasma in presence/absence of BAY1830839</measure>
    <time_frame>Day -1 period 1</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC of methotrexate in plasma in presence/absence of BAY1830839</measure>
    <time_frame>Day -1 period 1 (Dose group 3 of BAY1830839 only)</time_frame>
    <description>If AUC(tlast-∞) &gt;20% of AUC then AUC(0-tlast) will replace AUC.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Cmax of methotrexate in plasma in presence/absence of BAY1830839</measure>
    <time_frame>Day -1 period 1 (Dose group 3 of BAY1830839 only)</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Healthy Volunteers</condition>
  <arm_group>
    <arm_group_label>BAY1830839 arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Period 1: Dose 1, Dose 2, Dose 3, Dose 4, Dose 5 and Dose 6, single dose. Period 2: Dose 1, Dose 2 and Dose 3, once daily over 10 days. Dose 4 and Dose 5, twice daily over 10 days. Dose 6, single dose on Day 1, three times daily (TID) for 9 days (Days 2-10).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo arm</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo tablets matching BAY1830839</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BAY1830839</intervention_name>
    <description>Tablet, oral.</description>
    <arm_group_label>BAY1830839 arm</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Tablet, oral.</description>
    <arm_group_label>Placebo arm</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Midazolam</intervention_name>
    <description>For all dose steps. Oral. Two single doses. One dose administered during pre-dose in Period 1 and the second dose administered on the last day of treatment with BAY1830839 or placebo in Period 2</description>
    <arm_group_label>BAY1830839 arm</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Methotrexate</intervention_name>
    <description>Only for Dose 3 step. Tablet, oral. Two single doses. One dose administered during pre-dose in Period 1 and the second dose administered on the last day of treatment with BAY1830839 or placebo in Period 2.</description>
    <arm_group_label>BAY1830839 arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Participant must be 18 to 50 years of age inclusive, at the time of signing the&#xD;
             informed consent.&#xD;
&#xD;
          -  Overtly healthy as determined by medical evaluation including (medical and surgical&#xD;
             history, physical examination, laboratory tests, ECG, vital signs).&#xD;
&#xD;
          -  Confirmation of the participant's health insurance coverage prior to the first&#xD;
             screening examination/visit.&#xD;
&#xD;
          -  Body Mass Index (BMI): above or equal 18.5 and below or equal 30.0 kg/m² at screening&#xD;
&#xD;
          -  Male&#xD;
&#xD;
          -  Study participants of reproductive potential must agree to utilize two reliable and&#xD;
             acceptable methods of contraception simultaneously when sexually active. This applies&#xD;
             for the time period between admission to the study site until 12 weeks after the last&#xD;
             administration of the study intervention. The following contraceptive methods will be&#xD;
             regarded as adequate in the context of this study:&#xD;
&#xD;
        condoms (male or female) with or without a spermicidal agent;&#xD;
&#xD;
          -  diaphragm or cervical cap with spermicide;&#xD;
&#xD;
          -  intra-uterine device;&#xD;
&#xD;
          -  hormone-based contraception.&#xD;
&#xD;
               -  Capable of giving signed informed consent which includes compliance with the&#xD;
                  requirements and restrictions listed in the informed consent form (ICF) and in&#xD;
                  this protocol.&#xD;
&#xD;
               -  The informed consent must be signed before any study specific tests or procedures&#xD;
                  are done.&#xD;
&#xD;
               -  Ability to understand and follow study-related instructions&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Incompletely cured pre-existing diseases for which it can be assumed that the&#xD;
             absorption, distribution, metabolism, elimination and effects of the study drugs will&#xD;
             not be normal.&#xD;
&#xD;
          -  Relevant diseases within the last 4 weeks prior to the first study administration of&#xD;
             study intervention.&#xD;
&#xD;
          -  Febrile illness within 4 weeks before the first study administration of study&#xD;
             intervention.&#xD;
&#xD;
          -  Known hypersensitivity to any study intervention (active substances or excipients of&#xD;
             the preparations) to be used in the study.&#xD;
&#xD;
          -  Known severe allergies, significant non-allergic drug reactions, or multiple drug&#xD;
             allergies, e.g. allergies to more than 3 allergens, allergies affecting the lower&#xD;
             respiratory tract - allergic asthma, allergies requiring therapy with corticosteroids,&#xD;
             or urticaria.&#xD;
&#xD;
          -  Use of systemic or topical medicines or substances which oppose the study objectives&#xD;
             or which might influence them within 4 weeks before first study drug administration,&#xD;
             e.g. an investigational drug; any drug known to induce liver enzymes (e.g.&#xD;
             dexamethasone, barbiturates, rifampicin, anticonvulsants, griseofulvin, St. John's&#xD;
             Wort [Hypericum perforatum]).&#xD;
&#xD;
          -  History of COVID-19 as patients with a history of severe COVID-19 infection.&#xD;
&#xD;
          -  Incomplete SARS-CoV-2 vaccination&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Bayer Clinical Trials Contact</last_name>
    <phone>(+)1-888-84 22937</phone>
    <email>clinical-trials-contact@bayer.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Charité Research Organisation GmbH</name>
      <address>
        <city>Berlin</city>
        <zip>10117</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>May 27, 2019</study_first_submitted>
  <study_first_submitted_qc>May 27, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">May 29, 2019</study_first_posted>
  <last_update_submitted>November 5, 2021</last_update_submitted>
  <last_update_submitted_qc>November 5, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 8, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Methotrexate</mesh_term>
    <mesh_term>Midazolam</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
    <ipd_description>Availability of this study's data will be determined according to Bayer's commitment to the EFPIA/PhRMA &quot;Principles for responsible clinical trial data sharing&quot;. This pertains to scope, timepoint and process of data access.&#xD;
As such, Bayer commits to sharing upon request from qualified researchers patient-level clinical trial data, study-level clinical trial data, and protocols from clinical trials in patients for medicines and indications approved in the US and EU as necessary for conducting legitimate research. This applies to data on new medicines and indications that have been approved by the EU and US regulatory agencies on or after January 01, 2014.&#xD;
Interested researchers can use www.clinicalstudydatarequest.com to request access to anonymized patient-level data and supporting documents from clinical studies to conduct research. Information on the Bayer criteria for listing studies and other relevant information is provided in the Study sponsors section of the portal.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

